Articaine with epinephrine (dental cartridge)
آرتیکائین + اپینفرین (کارپول دندانپزشکی)
🧠 Nervous SystemDental local anaesthetic
Market / country: 🇺🇸 USA
Orabloc (US) · Septocaine (US)
🧮 Dose calculator
Local anaesthesia (infiltration / dental) · Regimen source: FDA Orabloc (articaine) · 2.2
- • Equals 0.175 mL/kg. Usual: infiltration 0.5–2.5 mL; nerve block 0.5–3.4 mL; oral surgery 1–5.1 mL. The calculated value is the ceiling. FDA Orabloc (articaine) · 2.2FDA Orabloc (articaine) · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Sulfite hypersensitivity. FDA Orabloc (articaine) · 4
- ⛔ Not established under 4 years. FDA Orabloc (articaine) · 8.4
Formulations
- 4% articaine + epinephrine 1:100,000 cartridge — injection 🇺🇸 USA FDA Orabloc (articaine) · 3
- 4% articaine + epinephrine 1:200,000 cartridge — injection 🇺🇸 USA FDA Orabloc (articaine) · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Orabloc (articaine) · 8.1
“Risk Summary Available data from postmarketing case reports over decades of clinical use with articaine and epinephrine during pregnancy have not identified any drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Orabloc (articaine) · 8.2
“Risk Summary There are no data on the presence of articaine with epinephrine in human milk, the effects on breastfed infants, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Orabloc (articaine) · 8.4
“The safety and effectiveness of ORABLOC for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Orabloc (articaine) · 8.5
“In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received another product containing articaine and epinephrine 1:100,000.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA022466
- DailyMed (FDA label)FDA Orabloc (articaine)
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDN01BB58
- Darooyab (Iran)Articaine-Epinephrine
🇮🇷 Registered in Iran Darooyab · G-4622/Articaine-Epinephrine
Dosage forms with Iranian generic codes, per Darooyab.
- 52282 · ARTICAINE / EPINEPHRINE INJECTION PARENTERAL 4 %/0.001 % 1.7 mL · فرآورده تزریقی آرتیکائین / اپینفرین ۴ درصد / ۰٫۰۰۱ درصد ۱٫۷ میلیلیتر
- 52283 · ARTICAINE / EPINEPHRINE INJECTION PARENTERAL 4 %/0.002 % 1.7 mL · فرآورده تزریقی آرتیکائین / اپینفرین ۴ درصد / ۰٫۰۰۲ درصد ۱٫۷ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Orabloc (articaine) · 3FDA Orabloc (articaine) · 2.2FDA Orabloc (articaine) · 2.1FDA Orabloc (articaine) · 4FDA Orabloc (articaine) · 8.4FDA Orabloc (articaine) · 8.1FDA Orabloc (articaine) · 8.2FDA Orabloc (articaine) · 8.5FDA Orabloc (articaine) · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4622/Articaine-Epinephrine
- Clinical review⚠ Unverified